Venture capital and the European biotechnology industry:
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
New York [u.a.]
Palgrave Macmillan
2009
|
| Edition: | 1. publ. |
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Item Description: | Includes bibliographical references and index |
| Physical Description: | VIII, 220 S. graph. Darst. |
| ISBN: | 9780230217195 |
Staff View
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV035262497 | ||
| 003 | DE-604 | ||
| 005 | 20210301 | ||
| 007 | t | ||
| 008 | 090122s2009 xxud||| |||| 00||| eng d | ||
| 010 | |a 2008029943 | ||
| 020 | |a 9780230217195 |c alk. paper |9 978-0-230-21719-5 | ||
| 035 | |a (OCoLC)234176084 | ||
| 035 | |a (DE-599)BVBBV035262497 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c US | ||
| 049 | |a DE-12 |a DE-188 |a DE-526 | ||
| 050 | 0 | |a HD9999.B443 | |
| 082 | 0 | |a 660.6068/1 | |
| 084 | |a QP 752 |0 (DE-625)141934: |2 rvk | ||
| 100 | 1 | |a Bains, William |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Venture capital and the European biotechnology industry |c William Bains |
| 250 | |a 1. publ. | ||
| 264 | 1 | |a New York [u.a.] |b Palgrave Macmillan |c 2009 | |
| 300 | |a VIII, 220 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 650 | 4 | |a Biotechnology industries |z Europe |x Finance | |
| 650 | 4 | |a Venture capital | |
| 650 | 0 | 7 | |a Biotechnologische Industrie |0 (DE-588)4208106-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Risikokapital |0 (DE-588)4124067-4 |2 gnd |9 rswk-swf |
| 651 | 4 | |a Europa | |
| 651 | 7 | |a Europa |0 (DE-588)4015701-5 |2 gnd |9 rswk-swf | |
| 689 | 0 | 0 | |a Europa |0 (DE-588)4015701-5 |D g |
| 689 | 0 | 1 | |a Biotechnologische Industrie |0 (DE-588)4208106-3 |D s |
| 689 | 0 | 2 | |a Risikokapital |0 (DE-588)4124067-4 |D s |
| 689 | 0 | |C b |5 DE-604 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017067999&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-017067999 | ||
Record in the Search Index
| _version_ | 1804138546253004801 |
|---|---|
| adam_text | Titel: Venture capital and the European biotechnology industry
Autor: Bains, William
Jahr: 2009
Contents
ListofTables vi
List ofFigures vii
1 Genes and Money in Europe: Why Did It Fail? 1
2 The Biotechnology Industry and Venture Capital 5
3 Europe Falls Behind 23
4 Why Does Europe Do So Poorly? Some Inadequate
Explanations 42
5 Underinvestment in European Biotechnology 55
6 Public Markets and Underinvestment 73
7 VC Management of Companies 86
8 VC Effects on Business Efficacy 109
9 Investor Blockade of Business 123
10 Pomp and Circumstance 140
11 The Real VC Business Model 150
12 What to Do about It: Government 173
13 What to Do about It: Business 189
Notes 198
References 201
Company Index 216
Topical Index 218
Tables
2.1 Comparative market capitalisations 20
3.1 VC and technology company formation activity in Canada 28
3.2 VC capacity versus population 29
4.1 Where biotechs collaborate 51
4.2 Government spend on health R D 53
5.1 Factors leading to company failure 56
7.1 NVT stay and company success 105
11.1 Compensation package for top US banks 155
12.1 Company change as a result of innovation 176
Figures
2.1 The money cascade for VC 11
2.2 Numbers of biotech companies 15
2.3 Market capitalization of public biotech companies 16
2.4 Total employed by the biotechnology industry,
US and Europe 16
2.5 Employment gap between the US and Europe 17
2.6 Cumulative drug approvals from biotech companies,
1980-2005 18
2.7 Market capitalization of public biotechnology companies,
end of 2005 19
2.8 Market capitalization excluding old giants 20
2.9 Biotech aggregate capitalisation versus country size 21
3.1 Rate of formation of early biotech start-ups 24
3.2 VC returns from European biotech VC funds 31
3.3 Simplified fund life cycle example 33
3.4 NASDAQ comparators for VC returns 36
3.5 Scientist career total earnings from different approaches
to science commercialisation 39
4.1 Business models for biotech companies in 1988 43
4.2 Survival of Cambridge area biotech companies 44
4.3 Date of foundation of 1998-vintage companies 45
4.4 Employment mobility in European biotech companies 48
4.5 Expatriate experience of European CXOs 49
4.6 Scientific publications by country 52
4.7 Origins of start-up companies 53
5.1 Amount invested in biotech by company age 57
5.2 Investment in UK and US biotech companies 58
5.3 Pharmaceutical company patent filings 60
5.4 Failure in UK biotechnology start-ups 64
5.5 Time taken to invest in UK biotech companies 65
5.6 Technical due diligence levels in start-up biotech fundings 67
6.1 Average pre-IPO valuation and average cash raised, US vs EU 75
6.2 US and European biotech IPOs 1995-2002 77
6.3 Investment versus deals for genomics companies 78
6.4 Time to IPO for European and US biotech companies 80
6-5 Ratio public to private sources of finance 83
vii
vili Figures
7.1 How long VCs look at different aspects of propositions 89
7.2 Reasons for VC rejection of business plans (UK) 90
7.3 Shareholder veto powers 92
7.4 European VC claims for non-financial support
for companies 95
7.5 Impact and cost of advice 96
7.6 Fraction of VC time spent in different activities 98
7.7 Investments per partner per year 99
7.8 How many Boards do VC investors sit on? 100
7.9 Survival of NVT after foundation 103
7.10 X-axis - share value today as a fraction of share value
at IPO 107
8.1 Business sector of public biotech companies (2004) 110
8.2 Business sector of private biotech companies (2004) 111
8.3 Industry areas of research-based biotech companies
in 1988 112
8.4 The medicines development process 113
8.5 Geron stock price 116
9.1 Preference share effects 124
9.2 Preference multiples in 44 UK biotech investments,
1998-2005 126
9.3 Causes and effects of Pref shares 127
9.4 Arakis exit outcomes for major share classes 133
9.5 Shareholder commonality in merged companies 135
9.6 Commercial outcomes of mergers 136
10.1 Big company experience and biotech success 143
10.2 Where do Pharma-experienced biotech execs come from 144
10.3 Management techniques used by SME technology
companies 148
11.1 VC yield from management and Carried Interest 154
11.2 Time gap between fund closings 157
11.3 VC funds raised versus VC-backed IPOs 158
11.4 Average size of specialist VC funds in Bio- and
general tech 168
11.5 Fund increase versus inter-fund gap 169
12.1 Unemployment versus small firm employment 178
12.2 Company creation versus national initiatives 180
13.1 Patent publications from some UK Universities 194
|
| any_adam_object | 1 |
| author | Bains, William |
| author_facet | Bains, William |
| author_role | aut |
| author_sort | Bains, William |
| author_variant | w b wb |
| building | Verbundindex |
| bvnumber | BV035262497 |
| callnumber-first | H - Social Science |
| callnumber-label | HD9999 |
| callnumber-raw | HD9999.B443 |
| callnumber-search | HD9999.B443 |
| callnumber-sort | HD 49999 B443 |
| callnumber-subject | HD - Industries, Land Use, Labor |
| classification_rvk | QP 752 |
| ctrlnum | (OCoLC)234176084 (DE-599)BVBBV035262497 |
| dewey-full | 660.6068/1 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 660 - Chemical engineering |
| dewey-raw | 660.6068/1 |
| dewey-search | 660.6068/1 |
| dewey-sort | 3660.6068 11 |
| dewey-tens | 660 - Chemical engineering |
| discipline | Chemie / Pharmazie Wirtschaftswissenschaften |
| edition | 1. publ. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01754nam a2200469zc 4500</leader><controlfield tag="001">BV035262497</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20210301 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">090122s2009 xxud||| |||| 00||| eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a">2008029943</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780230217195</subfield><subfield code="c">alk. paper</subfield><subfield code="9">978-0-230-21719-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)234176084</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV035262497</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-526</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HD9999.B443</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">660.6068/1</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QP 752</subfield><subfield code="0">(DE-625)141934:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bains, William</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Venture capital and the European biotechnology industry</subfield><subfield code="c">William Bains</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. publ.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York [u.a.]</subfield><subfield code="b">Palgrave Macmillan</subfield><subfield code="c">2009</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">VIII, 220 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biotechnology industries</subfield><subfield code="z">Europe</subfield><subfield code="x">Finance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Venture capital</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biotechnologische Industrie</subfield><subfield code="0">(DE-588)4208106-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Risikokapital</subfield><subfield code="0">(DE-588)4124067-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">Europa</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">Europa</subfield><subfield code="0">(DE-588)4015701-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Europa</subfield><subfield code="0">(DE-588)4015701-5</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Biotechnologische Industrie</subfield><subfield code="0">(DE-588)4208106-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Risikokapital</subfield><subfield code="0">(DE-588)4124067-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017067999&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-017067999</subfield></datafield></record></collection> |
| geographic | Europa Europa (DE-588)4015701-5 gnd |
| geographic_facet | Europa |
| id | DE-604.BV035262497 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T21:29:54Z |
| institution | BVB |
| isbn | 9780230217195 |
| language | English |
| lccn | 2008029943 |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-017067999 |
| oclc_num | 234176084 |
| open_access_boolean | |
| owner | DE-12 DE-188 DE-526 |
| owner_facet | DE-12 DE-188 DE-526 |
| physical | VIII, 220 S. graph. Darst. |
| publishDate | 2009 |
| publishDateSearch | 2009 |
| publishDateSort | 2009 |
| publisher | Palgrave Macmillan |
| record_format | marc |
| spelling | Bains, William Verfasser aut Venture capital and the European biotechnology industry William Bains 1. publ. New York [u.a.] Palgrave Macmillan 2009 VIII, 220 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Includes bibliographical references and index Biotechnology industries Europe Finance Venture capital Biotechnologische Industrie (DE-588)4208106-3 gnd rswk-swf Risikokapital (DE-588)4124067-4 gnd rswk-swf Europa Europa (DE-588)4015701-5 gnd rswk-swf Europa (DE-588)4015701-5 g Biotechnologische Industrie (DE-588)4208106-3 s Risikokapital (DE-588)4124067-4 s b DE-604 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017067999&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Bains, William Venture capital and the European biotechnology industry Biotechnology industries Europe Finance Venture capital Biotechnologische Industrie (DE-588)4208106-3 gnd Risikokapital (DE-588)4124067-4 gnd |
| subject_GND | (DE-588)4208106-3 (DE-588)4124067-4 (DE-588)4015701-5 |
| title | Venture capital and the European biotechnology industry |
| title_auth | Venture capital and the European biotechnology industry |
| title_exact_search | Venture capital and the European biotechnology industry |
| title_full | Venture capital and the European biotechnology industry William Bains |
| title_fullStr | Venture capital and the European biotechnology industry William Bains |
| title_full_unstemmed | Venture capital and the European biotechnology industry William Bains |
| title_short | Venture capital and the European biotechnology industry |
| title_sort | venture capital and the european biotechnology industry |
| topic | Biotechnology industries Europe Finance Venture capital Biotechnologische Industrie (DE-588)4208106-3 gnd Risikokapital (DE-588)4124067-4 gnd |
| topic_facet | Biotechnology industries Europe Finance Venture capital Biotechnologische Industrie Risikokapital Europa |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017067999&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT bainswilliam venturecapitalandtheeuropeanbiotechnologyindustry |